Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On?Demand Vardenafil for Pulmonary Hypertension

Stock Information for Gossamer Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gossamer Bio Inc.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio to Participate in Upcoming Investor Conferences
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio to Participate in Upcoming Investor Conferences
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.